Advertisement
MRK vs NVS
Which Stock Would AI Choose? Merck & Co. (MRK) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- MRK enters this comparison with stronger momentum, having rallied roughly 50% year-to-date amid positive late-stage cancer vaccine data and expanding oncology approvals.
- NVS has faced a more turbulent stretch, including trial setbacks and an activist shareholder call for board changes, weighing on relative performance.
- Both are diversified pharmaceutical leaders, but MRK leans heavily on a single oncology franchise (Keytruda), while NVS spans oncology, immunology, neuroscience, and cardiovascular medicine.
- Key risk profiles differ: MRK faces Keytruda's 2028 patent expiry, while NVS is navigating what management calls the largest patent expiry in company history.
- Analyst consensus is a "Buy" for MRK versus a more cautious "Hold" for NVS, reflecting differing near-term market positioning.
- For more detail on each company's major developments, explore MRK Major News and MRK Today's Price Move, as well as NVS Major News and NVS Today's Price Move.
- To see how AI-driven strategies are currently trading these and other tickers, explore the Trending AI Robots.
Introduction
Merck & Co. (MRK) and Novartis AG (NVS) are two of the world's largest pharmaceutical companies, and both are in the middle of pivotal transitions. MRK is defending and extending its dominance in oncology ahead of a major patent cliff, while NVS is rebalancing its portfolio toward high-growth, innovative medicines as legacy blockbusters face generic competition. This stock comparison is most relevant for healthcare-sector investors and traders evaluating relative performance, momentum, and risk across two large-cap names with distinct catalysts and market positioning.
MRK Overview and Recent Performance
Merck & Co. is a U.S.-based pharmaceutical leader whose business is anchored by Keytruda, one of the best-selling cancer immunotherapies in the world. In recent weeks, the stock has been driven by high-profile pipeline news: positive late-stage data for an investigational personalized melanoma vaccine developed with Moderna, used in combination with Keytruda, reinforced the company's oncology franchise and helped push shares to a fresh 52-week high. However, the stock pulled back after full trial results, disclosed ahead of schedule, came in below the more optimistic expectations some investors had set following earlier-stage data.
Financially, MRK reported a first-quarter net loss driven by acquisition-related charges, including its purchase of Cidara Therapeutics, even as sales rose year over year. Keytruda sales grew modestly in the first half, while newer products such as the pulmonary hypertension therapy Winrevair and the pneumococcal vaccine Capvaxive gained traction. Management continues to point to a diversified pipeline and recent acquisitions as the path through Keytruda's expected 2028 loss of exclusivity.
NVS Overview and Recent Performance
Novartis AG is a Swiss pharmaceutical company concentrated in innovative prescription medicines across oncology, immunology, neuroscience, and cardiovascular disease. Its recent market activity has been marked by volatility. Positive late-stage results for remibrutinib, an investigational oral treatment for relapsing multiple sclerosis (MS, a disease of the central nervous system), offered support, but full data showed efficacy below that of a competing drug from Roche, and shares declined.
This followed a series of setbacks, including disappointing results for the heart drug pelacarsen, a late-stage failure in a muscle-wasting program tied to the Avidity acquisition, and the halt of an experimental CAR-T cell therapy (a treatment that engineers a patient's immune cells to attack disease) after patient deaths. A major shareholder publicly called for board changes, adding governance pressure. On the operational side, NVS reported roughly flat first-quarter net sales as generic erosion offset strength in growth drivers such as Kisqali, Kesimpta, Pluvicto, and Leqvio, while facing the largest patent expiry in its history.
Trending AI Robots
Tickeron operates a marketplace of hundreds of AI trading bots that collectively trade thousands of different tickers, each built around distinct strategies, timeframes, and risk profiles. Because not every bot suits every market regime, Tickeron curates only the most relevant performers into its Trending AI Robots section. This selection highlights bots whose statistical profiles, win rates, and momentum align with current conditions, giving traders a focused view of AI-driven approaches rather than an unfiltered list. Bots vary widely in holding periods, from short-term swing strategies to longer trend-following systems, and in the specific equities they monitor. For investors interested in supplementing their own analysis with systematic, data-driven signals, exploring the Trending AI Robots page offers a practical starting point.
Head-to-Head Comparison
The two companies diverge most sharply on concentration and momentum. MRK remains heavily dependent on Keytruda, which creates both a powerful growth engine today and a concentrated patent-expiry risk in 2028. NVS is comparatively more diversified, but its portfolio is simultaneously absorbing generic erosion across multiple legacy products while relying on newer launches to offset the decline.
On growth drivers, MRK's narrative centers on oncology depth and pipeline optionality, including its cancer-vaccine program. NVS's story leans on a broad slate of growth medicines and share-buyback-driven shareholder returns, though its recent M&A (mergers and acquisitions) record has drawn investor criticism. In terms of relative performance, MRK has outpaced both its sector and the broader market year-to-date, while NVS has traded more defensively, with sentiment tempered by trial failures and governance scrutiny. Valuation also differs, with MRK carrying a higher forward earnings multiple consistent with its momentum, while NVS offers a comparatively lower multiple and a modest dividend yield.
Tickeron AI Verdict
Based on observable trend consistency, relative momentum, and catalyst quality, Tickeron's AI would likely favor MRK in the current environment. The stock's sustained uptrend, positive oncology data flow, and stronger analyst consensus suggest more favorable positioning than NVS, whose recent record of trial setbacks and governance pressure has introduced greater uncertainty. That said, MRK's Keytruda concentration remains a meaningful structural risk, and any deterioration in oncology sentiment could shift the balance. The assessment is probabilistic rather than definitive, reflecting the relative strength of each name's current signals rather than a forecast of guaranteed outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and NVS is a Buy.
Aroon Indicator for MRK shows an upward move is likely
MRK's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 265 similar instances where the Aroon Indicator showed a similar pattern. In 177 of the 265 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MRK as a result. In 55 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 30, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 27 of 50 cases over the following month. The odds of a continued upward trend are 54%.
MRK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 44%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.633) is normal, around the industry mean (-1.421). MRK's P/E Ratio (116.452) is considerably higher than the industry average of (21.700). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
NVS in upward trend: 10-day moving average moved above 50-day moving average on October 22, 2026
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 43 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 187 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.421). P/E Ratio (24.370) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).
MRK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 29 | 4 | |
SMR RATING 1..100 | 79 | 33 | |
PRICE GROWTH RATING 1..100 | 12 | 40 | |
P/E GROWTH RATING 1..100 | 1 | 12 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (54) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (88). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.
NVS's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as MRK (29). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (79). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (12) in the Pharmaceuticals Major industry is in the same range as NVS (40). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as NVS (12). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.
| MRK | NVS | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 54% |
| Stochastic ODDS (%) | 4 days ago 63% | 4 days ago 38% |
| Momentum ODDS (%) | 4 days ago 65% | 4 days ago 54% |
| MACD ODDS (%) | 4 days ago 54% | N/A |
| TrendWeek ODDS (%) | 4 days ago 49% | 4 days ago 56% |
| TrendMonth ODDS (%) | 4 days ago 57% | 4 days ago 51% |
| Advances ODDS (%) | 11 days ago 57% | 14 days ago 55% |
| Declines ODDS (%) | 4 days ago 51% | N/A |
| BollingerBands ODDS (%) | 6 days ago 57% | 4 days ago 30% |
| Aroon ODDS (%) | 4 days ago 67% | 4 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 3 FA rating(s) are green while NVS’s FA Score has 3 green FA rating(s).
- MRK’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 7 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
- MRK’s TA Score: 7 bullish, 2 bearish.
- NVS’s TA Score: 5 bullish, 4 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а -1.87% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.88%. For the same industry, the average monthly price growth was +1.80%, and the average quarterly price growth was +5.50%.
Reported Earning Dates
MRK is expected to report earnings on Feb 02, 2027.
NVS is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.88% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.